US2017035812A1PendingUtilityA1
Novel cell-derived composition
Assignee: NOVEOME BIOTHERAPEUTICS INCPriority: Dec 12, 2013Filed: Oct 10, 2016Published: Feb 9, 2017
Est. expiryDec 12, 2033(~7.4 yrs left)· nominal 20-yr term from priority
A61K 38/19C12N 2502/03C12N 5/0605C12N 2501/998C12N 2502/025C12N 2501/11A61K 35/50
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.
Claims
exact text as granted — not AI-modified1 .- 7 . (canceled)
8 . An Amnion-derived Cellular Cytokine Solution-B (ACCS-B) composition made by a method comprising the step of culturing Amnion-derived Multipotent Progenitor (AMP) cells in Basal Medium Eagle (BME) culture medium supplemented with human serum albumin and human EGF.
9 . A method promoting bone growth comprising the step of administering to a subject in need thereof a therapeutically effective dose of ACCS-B.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.